Pro-Dex (PDEX) Projected to Post Earnings on Thursday

Pro-Dex (NASDAQ:PDEX) is expected to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $13.80 million for the quarter.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pro-Dex Price Performance

PDEX opened at $33.25 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $45.78 and its 200 day moving average price is $35.26. Pro-Dex has a fifty-two week low of $16.18 and a fifty-two week high of $59.60. The firm has a market cap of $108.43 million, a price-to-earnings ratio of 16.54 and a beta of 0.53.

Insider Activity at Pro-Dex

In other news, Director Raymond E. Cabillot sold 1,100 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $45.01, for a total transaction of $49,511.00. Following the sale, the director now owns 318,652 shares in the company, valued at $14,342,526.52. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 27,770 shares of company stock valued at $1,239,312 over the last ninety days. Insiders own 47.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PDEX. Ascendiant Capital Markets increased their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com lowered Pro-Dex from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 3rd.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.